para-toluenesulfonamide (PTS100)

MCF-7 and MDA-MB-231 breast cancer cells were treated with PTS or subjected to hypoxic conditions using cobalt chloride (CoCl), with acetazolamide serving as a positive control. Collectively, our findings suggest that PTS inhibits breast cancer growth and metastasis through the p38 MAPK/ERK1/2 pathway. Moreover, PTS may have the potential to prevent the development of resistance to αPD-1 therapy in breast cancer.

PTS and cisplatin were found to have an obvious synergistic tumor-inhibiting effect on canine melanoma. PTS alone and PTS combined with cisplatin may be antitumor agents for canine melanoma treatment.

Aims To provide the first interim results of the «Study of REduction And DIscontinuation Treatment of TKI (READIT)» (NCT 04578847): evaluation of the response rates and first data of imatinib (IM) plasma blood concentrations after dose reduction...The TKI dose reduction phase consists of two 6 mo steps: 1st step (300 mg for IM, 400 mg for nilotinib (NIL), 50 mg for dasatinib (DAS) and 300 mg for bosutinib (BOS)) and 2nd step (25 mg for DAS and 200 mg for IM, NIL and BOS) of TKI dose reduction...At baseline 46 (66%) pts received IM (39 pts-400 mg, 3 pts–300 mg, 4 pts–200 mg) and 24 (34%) pts - second-generation (2G) TKI: NIL - 13 pts (6 pts-800-600 mg, 6 pts-400 mg, 1 pt–200 mg), DAS- 6 pts (4 pts-100-70 mg, 2 pts–50 mg), BOS- 5 pts (1 pt–500 mg, 2 pts–300 mg, 2 pts–200 mg)...The results will be updated within a longer follow-up in order to evaluate the impact of de-escalation phase on TFR rates. The role of different TKI concentrations will be studied.